Table 1 Clinicopathological characteristics of 277 patients with outlet obstruction in the training and verification cohorts
Variables | Training cohort (%) | Verification cohort (%) | P-value |
|---|---|---|---|
All patients | 218 | 59 | |
Age (years) | 0.494 | ||
60 | 111 (50.9%) | 33 (55.9%) | |
≥ 60 | 107 (49.1%) | 26 (44.1%) | |
Sex | 0.969 | ||
Male | 141 (64.7%) | 38 (64.4%) | |
Female | 77 (35.3%) | 21 (35.6%) | |
BMI (kg/m2) | 0.397 | ||
18.5 | 56 (25.7%) | 12 (20.3%) | |
≥ 18.5 | 162 (74.3%) | 47 (79.7%) | |
Preoperative weight loss | 0.117 | ||
3% | 36 (16.5%) | 15 (25.4%) | |
≥ 3% | 182 (83.5%) | 44 (74.6%) | |
GOOSS | 0.341 | ||
0/1 | 103 (47.2%) | 32 (54.2%) | |
2/3 | 115 (52.8%) | 27 (45.8%) | |
PS | 0.681 | ||
0/1 | 161 (73.9%) | 42 (71.2%) | |
2/3 | 57 (26.1%) | 17 (28.8%) | |
Extent of tumor | 0.474 | ||
Distal stomach | 184 (84.4%) | 52 (88.1%) | |
Total stomach | 34 (15.6%) | 7 (11.9%) | |
Surgical procedure | < 0.001 | ||
Radical gastrectomy | 85 (39.0%) | 38 (64.4%) | |
Palliative gastrectomy | 133 (61.0%) | 21 (35.6%) | |
Intraoperative blood loss | 0.912 | ||
< 100 ml | 32 (14.7%) | 9 (15.3%) | |
≥ 100 ml | 186 (85.3%) | 50 (84.7%) | |
Period of chemotherapy | 0.758 | ||
0 | 66 (30.3%) | 19 (32.2%) | |
1–7 | 101 (46.3%) | 27 (45.8%) | |
≥ 8 | 51 (23.4%) | 13 (22.0%) | |
T stage | 0.659 | ||
T1-T3 | 54 (24.8%) | 13 (22.0%) | |
T4a | 115 (52.8%) | 32 (54.2%) | |
T4b | 49 (22.4%) | 14 (23.8%) | |
N stage | 0.175 | ||
N0-N2 | 67 (30.7%) | 24 (40.7%) | |
N3a | 70 (32.1%) | 17 (28.8%) | |
N3b | 81 (37.2%) | 18 (30.5%) | |
M stage | < 0.001 | ||
M0 | 87 (39.9%) | 39 (66.1%) | |
M1 | 131 (60.1%) | 20 (33.9%) | |
Differentiation status | 0.093 | ||
Poor | 195 (89.4%) | 48 (81.4%) | |
Well or Moderate | 23 (10.6%) | 11 (18.6%) | |
Tumor size (cm) | 0.123 | ||
≤ 5 | 69 (31.7%) | 25 (42.4%) | |
5 | 149 (68.3%) | 34 (57.6%) | |
Complications | 0.885 | ||
No | 190 (87.2%) | 51 (86.4%) | |
Yes | 28 (12.8%) | 8 (13.6%) | |
CEA (ng/mL) | 0.156 | ||
5 | 174 (79.8%) | 42 (71.2%) | |
≥ 5 | 44 (20.2%) | 17 (28.8%) | |
CA19-9 (U/mL) | 0.666 | ||
27 | 145 (66.5%) | 41 (69.5%) | |
≥ 27 | 73 (33.5%) | 18 (30.5%) | |
HGB (g/L) | 0.897 | ||
≤ 120 | 131 (60.1%) | 36 (61.0%) | |
120 | 87 (39.9%) | 23 (39.0%) | |
WBC (× 109 /L) | 0.643 | ||
≤ 9.5 | 200 (91.7%) | 53 (89.8%) | |
9.5 | 18 (8.3%) | 6 (10.2%) | |
SII | 0.480 | ||
1185.2 | 165 (75.7%) | 42 (71.2%) | |
≥ 1185.2 | 53 (24.3%) | 17 (28.8%) | |
PNI | 0.439 | ||
36.5 | 22 (10.1%) | 4 (6.8%) | |
≥ 36.5 | 196 (89.9%) | 55 (93.2%) | |
Fibrinogen | 0.434 | ||
Normal | 159 (72.9%) | 46 (78.0%) | |
Elevated | 59 (27.1%) | 13 (22.0%) | |
Na (mmol/L) | 0.869 | ||
≤ 137 | 35 (16.1%) | 10 (16.9%) | |
137 | 183 (83.9%) | 49 (83.1%) | |
K (mmol/L) | 0.920 | ||
≤ 3.5 | 18 (8.3%) | 4 (6.8%) | |
3.5 | 200 (91.7%) | 55 (93.2%) |